背景:接受常规治疗的慢性甲状旁腺功能减退症(CHPT)患者会出现几种长期并发症,包括基底节钙化,后囊下白内障,肾结石,和肾功能不全。这项研究的目的是评估CHPT患者这些并发症的患病率和相关因素。
方法:我们进行了一项横断面研究,包括58例CHPT患者。所有参与者都接受了体检,生化评估(血清总钙,血清磷,血清白蛋白,完整的PTH,血清镁,25-羟基维生素D,血清肌酐,促甲状腺激素(TSH),和24小时尿钙),裂隙灯检查,脑计算机断层扫描(CT扫描),还有肾脏超声.
结果:参与者的平均年龄为52.6±16.4岁,性别比例(女性/男性)为3.5。Fahr综合征,白内障,尿石症,55%的人发现肾功能衰竭,62%,12%,17%的病例,分别。CHPT持续时间>15年(调整后-OR=43.1,95-CI:2.63-703.06,p=0.008)和治疗依从性差(调整后-OR=8.04,95%-CI:1.52-42.42,p=0.014)与Fahr综合征的风险独立相关。年龄>55岁(调整后的OR=5.07,95-CI:1.10-23.42,p=0.037),病程>15年(调整后的OR=20.21,95-CI:1.54-265.84,p=0.022),镁水平<0.8mmol/l(校正OR=36.46,95-CI:3.75-354.08,p=0.002)与囊膜下白内障的风险独立相关。只有高钙尿症(校正OR=21.27,95-CI:2.31-195.91,p=0.007)是肾结石的独立危险因素。肾衰竭与肾结石无关(p=1)。然而,肌酐清除率与年龄(r=-0.784;p<10-3)和病程(r=-0.352;p=0.007)呈负相关.
结论:我们的结果显示,神经系统疾病的患病率很高,眼,和CHPT患者的肾脏并发症,并强调定期生物监测的重要性,治疗调整,筛选,并坚持治疗以预防这些并发症。
BACKGROUND: Patients with Chronic hypoparathyroidism (CHPT) receiving conventional treatment are exposed to several long-term complications including basal ganglia calcifications, posterior subcapsular cataract, kidney stones, and renal insufficiency. The aim of this study was to assess the prevalence and the associated factors of these complications in patients with CHPT.
METHODS: We conducted a cross-sectional study including 58 patients with CHPT. All participants underwent physical examination, biochemical assessment (total serum calcium, serum phosphorus, serum albumin, intact-PTH, serum magnesium, 25-hydroxy-vitamin D, serum creatinine, thyroid stimulating hormone (TSH), and 24-hour urinary calcium), slit lamp examination, brain computed tomography scan (CT-scan), and renal ultrasound.
RESULTS: Participants had a mean age of 52.6 ± 16.4 years and a gender ratio (women/men) of 3.5. Fahr syndrome, cataract, urolithiasis, and renal failure were found in 55%, 62%, 12%, and 17% of cases, respectively. CHPT duration >15 years (Adjusted-OR = 43.1, 95-CI: 2.63-703.06, p = 0.008) and poor adherence to treatment (Adjusted-OR = 8.04, 95%-CI: 1.52-42.42, p = 0.014) were independently associated with the risk of Fahr syndrome. Age >55 years (adjusted-OR = 5.07, 95-CI: 1.10-23.42, p = 0.037), disease duration >15 years (adjusted-OR = 20.21, 95-CI: 1.54-265.84, p = 0.022), and magnesium level <0.8 mmol/l (adjusted-OR = 36.46, 95-CI: 3.75-354.08, p = 0.002) were independently associated with the risk of subcapsular cataract. Only hypercalciuria (Adjusted-OR = 21.27, 95-CI: 2.31-195.91, p = 0.007) was an independent risk factor for kidney stones. Renal failure was not associated with kidney stones (p = 1). However, creatinine clearance was negatively correlated with age (r = -0.784; p < 10-3) and disease duration (r = -0.352; p = 0.007).
CONCLUSIONS: Our results revealed high prevalences of neurological, ocular, and renal complications in patients with CHPT and emphasized the importance of regular biological monitoring, therapeutic adjustments, screening, and adherence to treatment in the prevention of these complications.